Study of COPD Subgroups and Biomarkers (NCT01969344)
Subpopulations and Intermediate Outcome Measures in COPD Study
🩺 Plain-English Summary (8th-Grade Level)
SPIROMICS I, SPIROMICS II, and SPIROMICS III are longitudinal observational studies of Chronic Obstructive Pulmonary Disease (COPD) cohort. SPIROMICS I had two primary aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not COPD is getting worse and to provide new ways of testing whether a new treatment is working. SPIROMICS II had three primary aims: (1) To define the natural history of "smokers with symptoms despite preserved spirometry" and characterize the airway mucus abnormalities underlying this condition; (2) To determine the radiographic precursor lesion(s) for emphysema and identify the molecular phenotypes underlying airway disease and emphysema; (3) To advance understanding of the biology of COPD exacerbations through analysis of predisposing baseline phenotypes, exacerbation triggers and host inflammatory response. SPIROMICS III has three primary aims: (1) To identify the main forms of smoking-related airway disease that are caused by pathological airway mucus, their biological underpinnings, and their physiological significance; (2) To identify longitudinal trajectories in established and novel CT measures of emphysema, test how they predict COPD progression, and define their underlying biology; (3) To identify environmental and social determinants of health that impact disease severity and progression and their influence on lung structure, biology, and health disparities in COPD.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 40 Years to 80 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Mayo Clinic Arizona — Scottsdale, Arizona
- University of California at Los Angeles — Los Angeles, California
- University of California at San Francisco — San Francisco, California
- National Jewish Health — Denver, Colorado
- University of Illinois at Chicago — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- Johns Hopkins University — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- Weill Cornell Medicine — New York, New York
- Columbia University — New York, New York
- Wake Forest University — Winston-Salem, North Carolina
- Temple University — Philadelphia, Pennsylvania
- University of Utah — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COPD
- Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound — Calgary,
- Impairments That Affect Correct Inhaler Use in COPD — Birmingham, Alabama
- The Development of an Integrated Physical Activity and Mental Health Intervention for Veterans With COPD, Emotion Distress, and Low Physical Activity — Boston, Massachusetts
- A Study to Evaluate Solrikitug in Participants With COPD (ZION) — Birmingham, Alabama
- RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD — Calgary, Alberta
- Evaluation of the Safety and Efficacy of TLD in Patients with COPD — Birmingham, Alabama
Explore by condition: All COPD clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.